| [1] |
Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74(3):229-263.
|
| [2] |
袁之俊, 来茂德. 结直肠癌分子分型与免疫治疗和靶向治疗[J]. 临床与实验病理学杂志, 2024, 40(6):561-566.
|
|
Yuan ZJ, Lai MD. Molecular typing of colorectal cancer and immunotherapy and targeted therapy[J]. J Clin Exp Pathol, 2024, 40(6):561-566.
|
| [3] |
刘亭. 贝伐珠单抗联合化疗治疗转移性结直肠癌疗效及安全性的长期随访观察[D]. 蚌埠: 蚌埠医学院, 2021.
|
|
Liu T. Long-term follow-up study of the efficacy and safety of bevacizumab combined with chemotherapy in the treatment of metastatic colorectal cancer[D]. Bengbu: Bengbu Medical College, 2021.
|
| [4] |
祝龙玲, 蒋晓莲, 彭维雪, 等. 乳腺癌术后化疗患者症状群的纵向研究[J]. 护理学杂志, 2022, 37(20):23-27.
|
|
Zhu LL, Jiang XL, Peng WX, et al. Longitudinal analysis of symptom clusters in chemotherapy patients after breast cancer surgery[J]. J Nurs Sci, 2022, 37(20):23-27.
|
| [5] |
Hevey D. Network analysis:a brief overview and tutorial[J]. Health Psychol Behav Med, 2018, 6(1):301-328.
DOI
URL
|
| [6] |
Epskamp S, Borsboom D, Fried EI. Estimating psychological networks and their accuracy:a tutorial paper[J]. Behav Res Methods, 2018, 50(1):195-212.
DOI
PMID
|
| [7] |
Wang XS, Wang Y, Guo H, et al. Chinese version of the M.D.Anderson Symptom Inventory:validation and application of symptom measurement in cancer patients[J]. Cancer, 2004, 101(8):1890-1901.
DOI
URL
|
| [8] |
顾铭. 安德森症状评估量表大肠癌模块的编制及应用研究[D]. 上海: 上海中医药大学, 2019.
|
|
Gu M. Development and application of the colorectal cancer module based on M.D. Anderson Symptom Inventory[D]. Shanghai: Shanghai University of Traditional Chinese Medicine, 2019.
|
| [9] |
Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy Scale:development and validation of the general measure[J]. J Clin Oncol, 1993, 11(3):570-579.
DOI
PMID
|
| [10] |
万崇华, 孟琼, 汤学良, 等. 癌症患者生命质量测定量表FACT-G中文版评介[J]. 实用肿瘤杂志, 2006(1):77-80.
|
|
Wan CH, Meng Q, Tang XL, et al. The Chinese version of FACT-G form in evaluation of quality of life for patients with cancer[J]. J Pract Oncol, 2006(1):77-80.
|
| [11] |
郑存风, 王峥, 刘海静, 等. 结直肠癌术后化疗患者核心症状的纵向研究及护理对策[J]. 中华护理杂志, 2025, 60(11):1309-1315.
DOI
|
|
Zheng CF, Wang Z, Liu HJ, et al. Longitudinal study on core symptoms and nursing strategies for patients with colorectal cancer undergoing postoperative chemotherapy[J]. Chin J Nurs, 2025, 60(11):1309-1315.
DOI
|
| [12] |
Cremolini C, Rossini D, Dell’Aquila E, et al. Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan:a phase 2 single-arm clinical trial[J]. JAMA Oncol, 2019, 5(3):343-350.
DOI
PMID
|
| [13] |
邹炎铃, 李易, 张紫嫣, 等. 基于体质特征的胃癌化疗患者核心症状及影响因素研究[J]. 中华护理杂志, 2024, 59(18):2238-2243.
|
|
Zou YL, Li Y, Zhang ZY, et al. Examining core symptoms and influencing factors of patients with gastric cancer undergoing chemotherapy:the role of Traditional Chinese Medicine constitutional traits[J]. Chin J Nurs, 2024, 59(18):2238-2243.
|
| [14] |
陈亚琼, 周建荣, 杨靖. 鼻咽癌患者同步放化疗期间的症状群及影响因素研究[J]. 重庆医科大学学报, 2014, 39(12):1830-1834.
|
|
Chen YQ, Zhou JR, Yang J. Symptom clusters and influencing factors for patients with nasopharyngeal carcinoma undergoing concurrent chemoradiation therapy[J]. J Chongqing Med Univ, 2014, 39(12):1830-1834.
|
| [15] |
冯芳茗, 张伟英, 何佳倩, 等. 消化道癌症患者化疗期间症状群及影响因素分析[J]. 解放军护理杂志, 2020, 37(9):13-17.
|
|
Feng FM, Zhang WY, He JQ, et al. Symptom clusters and influencing factors for patients with gastrointestinal cancer during chemotherapy[J]. Nurs J Chin PLA, 2020, 37(9):13-17.
|
| [16] |
周海英, 张玉侠, 陈潇, 等. 肝癌患者术后恶心呕吐发生现况及影响因素研究[J]. 中华护理杂志, 2022, 57(2):182-187.
DOI
|
|
Zhou HY, Zhang YX, Chen X, et al. The incidence and risk factors of postoperative nausea and vomiting in liver cancer[J]. Chin J Nurs, 2022, 57(2):182-187.
DOI
|
| [17] |
Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management[J]. Ann Pharmacother, 2009, 43(3):490-501.
DOI
PMID
|
| [18] |
Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and che-motherapy as initial treatment for metastatic colorectal cancer[J]. N Engl J Med, 2009, 360(14):1408-1417.
DOI
URL
|